Olga_Maria Iova

Ms. Olga_Maria Iova


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
OIOlga_Maria Iova
Olga_Maria Iova
GMGheorghe-Eduard Marin
Gheorghe-Eduard Marin
ILIzabella Lazar
Izabella Lazar
ISIoana C. Stănescu
Ioana C. Stănescu
GDGabriela Dogaru
Gabriela Dogaru
Adriana Elena BulboacăAdriana Elena Bulboacă
Adriana Elena Bulboacă
Nitric oxide, a ubiquitous molecule found throughout the natural world, is a key molecule implicated in many central and benefic molecular pathways and has a well-established role in the function of the central nervous system, as numerous studies have previously shown. Dysregulation of its metabolism, mainly the upregulation of nitric oxide production, has been proposed as a trigger and/or aggravator for many neurological affections. Increasing evidence supports the implication of this molecule in prevalent neurodegenerative diseases, such as Parkinson’s disease, Alzheimer’s disease, or amyotrophic lateral sclerosis. The mechanisms proposed for its neurotoxicity mainly center around the increased quantities of nitric oxide that are produced in the brain, their cause, and, most importantly, the pathological metabolic cascades created. These cascades lead to the formation of neuronal toxic substances that impair the neurons’ function and structure on multiple levels. The purpose of this review is to present the main causes of increased pathological production, as well as the most important pathophysiological mechanisms triggered by nitric oxide, mechanisms that could help explain a part of the complex picture of neurodegenerative diseases and help develop targeted therapies.

29 July 2025 in Applied Sciences
Verified
Journal Article
Open access
PDF file
OIOlga_Maria Iova
Olga_Maria Iova
GMGheorghe-Eduard Marin
Gheorghe-Eduard Marin
Ana-Maria VlaseAna-Maria Vlase
Ana-Maria Vlase
MAMarcela Achim
Marcela Achim
Dana Maria MunteanDana Maria Muntean
Dana Maria Muntean
Gabriela Adriana FilipGabriela Adriana Filip
Gabriela Adriana Filip
Anthyllis vulneraria is a traditional medicinal plant with confirmed anti-inflammatory properties, attributed to its high polyphenolic content. This study aimed to evaluate the wound-healing potential of A. vulneraria leaf extract in a rat burn model. Four groups of eight Wistar rats each received the following daily topical applications for 14 days: vehicle cream (negative control); silver sulfadiazine (positive control); or plant-based creams containing either 1 mg/cm2 or 2 mg/cm2 of polyphenols (experimental groups 1 and 2, respectively). On days 7 and 14, four animals per group were euthanized for histological and oxidative stress evaluations. LC-MS/MS analysis of the leaf extract identified hyperoside, ferulic acid, and p-coumaric acid as major constituents. Experimental group 1 showed significantly enhanced wound closure on days 5 and 7, while group 2 exhibited a significant effect on day 5. All oxidative stress markers, except catalase activity, differed significantly among the groups, with the most favorable results observed in group 2. IL-8 levels decreased after the extract treatment, while no significant microscopic changes were observed. These results indicate that A. vulneraria leaf extract may serve as a valuable adjuvant in burn wound healing.

Verified
Journal Article
Open access
PDF file
OIOlga_Maria Iova
Olga_Maria Iova
GMGheorghe-Eduard Marin
Gheorghe-Eduard Marin
VRVlad Răzniceanu
Vlad Răzniceanu
ȘMȘtefania-Maria Mocrei-Rebrean Ștefania-Maria Mocrei-Rebrean
Ștefania-Maria Mocrei-Rebrean Ștefania-Maria Mocrei-Rebrean
SPSebastian Romeo Pintilie
Sebastian Romeo Pintilie
Ioana Berindan-NeagoeIoana Berindan-Neagoe
Ioana Berindan-Neagoe
Anaplastic thyroid carcinoma (ATC) represents the most aggressive thyroid malignancy, characterized by rapid progression, therapeutic resistance, and poor prognosis. Conventional treatments remain largely ineffective, highlighting the need for novel therapies. Metabolic reprogramming, particularly the Warburg effect (WE), has emerged as a promising area of investigation. This review synthesizes current evidence on the role of WE in ATC and PDTC, integrating data from molecular profiling, preclinical studies, and emerging therapeutic strategies. Oncogenic alterations frequently observed in ATC, including mutations in BRAF, RAS, TP53, and activation of PI3K/AKT/mTOR and HIF-1α signaling, converge to promote glycolytic reprogramming. This metabolic shift supports tumor proliferation, immune evasion, and metastasis through increased glucose uptake, lactate production, and microenvironmental remodeling. Key metabolic nodes, including glucose transporters, hexokinase, and monocarboxylate transporters, are regarded as promising targets. Preclinical studies suggest that pharmacological inhibition of these pathways reduces tumor growth, enhances radiosensitivity, and improves response to targeted therapies. Future efforts should focus on combination therapies, biomarker-driven patient stratification, and the development of targeted delivery systems to overcome toxicity and resistance. A deeper understanding of tumor metabolic heterogeneity will be essential for translating these approaches into clinical practice.

23 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
OIOlga_Maria Iova
Olga_Maria Iova
GMGheorghe-Eduard Marin
Gheorghe-Eduard Marin
VRVlad Răzniceanu
Vlad Răzniceanu
ȘMȘtefania-Maria Mocrei-Rebrean Ștefania-Maria Mocrei-Rebrean
Ștefania-Maria Mocrei-Rebrean Ștefania-Maria Mocrei-Rebrean
SPSebastian Romeo Pintilie
Sebastian Romeo Pintilie
Ioana Berindan-NeagoeIoana Berindan-Neagoe
Ioana Berindan-Neagoe
Anaplastic thyroid carcinoma (ATC) and poorly differentiated thyroid carcinoma (PDTC) represent the most aggressive thyroid malignancies, characterized by rapid progression, therapeutic resistance, and poor prognosis. Conventional treatments remain largely ineffective, highlighting the need for novel therapies. Metabolic reprogramming, particularly the Warburg effect (WE), has emerged as a potential therapeutic target. This review synthesizes current evidence on the role of WE in ATC and PDTC, integrating data from molecular profiling, preclinical studies, and emerging therapeutic strategies. Oncogenic alterations frequently observed in ATC and PDTC, including mutations in BRAF, RAS, TP53, and activation of PI3K/AKT/mTOR and HIF-1α signaling, converge to promote glycolytic reprogramming. This metabolic shift supports tumor proliferation, immune evasion, and metastasis through increased glucose uptake, lactate production, and microenvironmental remodeling. Key metabolic nodes, including glucose transporters, hexokinase, and monocarboxylate transporters, are regarded as promising targets. Preclinical studies demonstrate that pharmacological inhibition of these pathways reduces tumor growth, enhances radiosensitivity, and improves response to targeted therapies. Future efforts should focus on combination therapies, biomarker-driven patient stratification, and the development of targeted delivery systems to overcome toxicity and resistance. A deeper understanding of tumor metabolic heterogeneity will be essential for translating these approaches into clinical practice.